SCHEMBL1623706

SCHEMBL1623706

COC(=O)c1cc2c(cnn2C(C)=O)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.39
PKM P14618 2/20 0.39
GSK3A P49840 2/20 0.39
CHEK1 O14757 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
CSNK1A1 P48729 1/20 0.39
LIMK1 P53667 1/20 0.39
IKBKE Q14164 1/20 0.39
MAPK14 Q16539 1/20 0.39
TAOK1 Q7L7X3 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
ICAM1 P05362 1/20 0.38
SELE P16581 1/20 0.38
VCAM1 P19320 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
CREBBP Q92793 1/20 0.38
RPS6KB1 P23443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16408743 0.82 PKM (0.44) NPC1PKMGSK3AICAM1SELE
SCHEMBL2176791 0.78 PKM (0.41) NPC1PKMGSK3AICAM1SELE
SCHEMBL23418579 0.77 ICAM1 (0.39) NPC1PKMGSK3AICAM1SELE
SCHEMBL16403549 0.76 CHEK1 (0.44) PKMGSK3ACHEK1AURKADAPK3
SCHEMBL1623758 0.75 IKBKE (0.43) NPC1GSK3ACHEK1AURKADAPK3
SCHEMBL6204919 0.73 GPR35 (0.43) GSK3AAURKADAPK3ICAM1SELE
SCHEMBL18549584 0.72 CHEK1 (0.40) PKMGSK3ACHEK1AURKADAPK3
SCHEMBL19439584 0.71 PTPN2 (0.49) NPC1PKMGSK3AICAM1SELE
SCHEMBL27946639 0.71 UCHL1 (0.45) PKMCCNCCDK8HPGDALDH1A1
SCHEMBL1623506 0.70 KDM4E (0.42) NPC1PKMGSK3ACHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor HUTCHISON MEDIPHARMA LTD (CN) 2025-03-27 US disclosed
US-20240139182-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor HUTCHISON MEDIPHARMA LTD (CN) 2024-05-02 US disclosed
US-11896592-B2 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor HUTCHISON MEDIPHARMA LIMITED (CN) 2024-02-13 US disclosed
EP-3795573-B1 CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LTD (CN) 2022-07-06 EP disclosed
EP-3795573-B1 CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LTD (CN) 2022-07-06 EP disclosed
EP-3340982-B1 COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2021-12-15 EP disclosed
EP-3340982-B1 COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2021-12-15 EP disclosed
US-11052141-B1 Method of modifying the immune response KODE BIOTECH LIMITED (NZ) 2021-07-06 US disclosed
US-20210154192-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2021-05-27 US disclosed
US-20210154192-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2021-05-27 US disclosed
US-20080293714-A1 Tec Kinase Inhibitors BENTZIEN JOERG MARTIN 2008-11-27 US disclosed
US-20080293714-A1 Tec Kinase Inhibitors BENTZIEN JOERG MARTIN 2008-11-27 US disclosed
EP-1968580-A2 2-(IH-THIENO [3,2-C] PYRAZOL-3YL)-IH-INDOLE DERIVATIVES AND RELATED COMPOUNDS AS TEC KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AND IMMUNOLOGICAL DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-17 EP disclosed
US-20070254937-A1 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2007-11-01 US disclosed
US-20070254937-A1 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2007-11-01 US disclosed
US-20070254937-A1 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2007-11-01 US disclosed
WO-2007076228-A2 2-(IH-THIENO [3,2-C] PYRAZOL-3YL)-IH-INDOLE DERIVATIVES AND RELATED COMPOUNDS AS TEC KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AND IMMUNOLOGICAL DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-05 WO disclosed
WO-2007076228-A2 2-(IH-THIENO [3,2-C] PYRAZOL-3YL)-IH-INDOLE DERIVATIVES AND RELATED COMPOUNDS AS TEC KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AND IMMUNOLOGICAL DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-05 WO disclosed
EP-1682553-A1 THIENOPYRAZOLES Aventis Pharmaceuticals Inc. (US) 2006-07-26 EP disclosed
WO-2005026175-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052141-B1 Method of modifying the immune response HLA-C, CD74, HLA-DRB1 NPC1 367/4885PKM 3609/4885GSK3A 4518/4885
US-20210154192-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR KCNJ11, NISCH, CYP4Z1 NPC1 2546/4885PKM 1157/4885GSK3A 1051/4885
US-11896592-B2 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor TK2, TYMP, DPYD NPC1 2300/4885PKM 465/4885GSK3A 843/4885
US-20070254937-A1 Thienopyrazoles ITK, IL2, JAK2 NPC1 4164/4885PKM 669/4885GSK3A 618/4885
US-20080293714-A1 Tec Kinase Inhibitors TEC, ITK, TXK NPC1 4218/4885PKM 780/4885GSK3A 261/4885
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor KCNJ11, NISCH, CYP4Z1 NPC1 2546/4885PKM 1157/4885GSK3A 1051/4885
US-20240139182-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor KCNJ11, NISCH, CYP4Z1 NPC1 2546/4885PKM 1157/4885GSK3A 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.